SCHEMBL6237639

SCHEMBL6237639

CC(C)COC(=O)NCc1ccccc1

nearest known ligand 0.58

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.57
MAPT P10636 3/20 0.57
MEN1 O00255 2/20 0.57
KMT2A Q03164 2/20 0.57
HDAC1 Q13547 1/20 0.56
L3MBTL1 Q9Y468 2/20 0.55
LMNA P02545 1/20 0.55
ALOX12 P18054 1/20 0.52
NPC1 O15118 1/20 0.51
RAB9A P51151 1/20 0.51
KDM4E B2RXH2 1/20 0.51
TSHR P16473 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2556067 0.90 MAPT (0.50) ALDH1A1MAPTMEN1KMT2AHDAC1
SCHEMBL28018053 0.89 MAPT (0.54) ALDH1A1MAPTMEN1KMT2AL3MBTL1
SCHEMBL3710489 0.85 HDAC1 (0.49) ALDH1A1MAPTMEN1KMT2AHDAC1
SCHEMBL22214985 0.84 MEP1B (0.54) HDAC1
SCHEMBL27705377 0.84 MAPT (0.52) ALDH1A1MAPTMEN1KMT2AL3MBTL1
SCHEMBL847829 0.84 HDAC1 (0.48) ALDH1A1MAPTMEN1KMT2AHDAC1
SCHEMBL19748921 0.82 HDAC1 (0.43) ALDH1A1MAPTMEN1KMT2AHDAC1
SCHEMBL2303306 0.82 CA12 (0.70) MAPTKMT2AL3MBTL1
SCHEMBL2577057 0.82 MMP8 (0.60) ALDH1A1MAPTKMT2AL3MBTL1
SCHEMBL2303305 0.82 CA12 (0.70) MAPTKMT2AL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116347985-A Agrochemical adjuvant 禾大国际股份公开有限公司 2023-06-27 CN disclosed
US-20230159569-A1 DUAL HDAC6/PROTEASOME INHIBITORS, AND METHODS OF USE THEREOF UNIVERSITY OF MARYLAND, BALTIMORE (US) 2023-05-25 US disclosed
US-11278634-B1 Stable parenteral composition of lacosamide EXTROVIS AG (CH) 2022-03-22 US disclosed
WO-2011130615-A2 PREPARATION OF LACOSAMIDE DR. REDDY'S LABORATORIES LTD. (IN) 2011-10-20 WO disclosed
US-7449447-B2 Peptidomimetic NS3-serine protease inhibitors of hepatitis C virus SCHERING CORPORATION (US) 2008-11-11 US disclosed
US-7247617-B2 Sixteen-member macrolide antiinfective agents KOSAN BIOSCIENCES INCORPORATED (US) 2007-07-24 US disclosed
US-6927290-B2 Production of mixed acid anhydride and amide compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2005-08-09 US disclosed
EP-1160236-B1 Production of mixed acid anhydride and amine compound SUMITOMO CHEMICAL CO (JP) 2005-05-25 EP disclosed
US-20040210059-A1 Production of mixed acid anhydride and amide compound SUMITOMO CHEMICAL COMPANY, LIMITED 2004-10-21 US disclosed
US-6753431-B2 REACTING A CARBAMATE DERIVATIVE WITH CARBOXYLIC AND HALOFORMIC ACID DERIVATIVES SUMITOMO CHEMICAL COMPANY LIMITED (JP) 2004-06-22 US disclosed
US-20020032346-A1 Production of mixed acid anhydride and amide compound SUMITOMO CHEMICAL CO., LTD. 2002-03-14 US disclosed
EP-1160236-A2 Production of mixed acid anhydride and amine compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2001-12-05 EP disclosed
CN-1091425-A Heterocyclic neophenan analogs, process for their preparation and their use as pesticides HOECHST AG (DE) 1994-08-31 CN disclosed
US-4122090-A Cyclic esters of 3,4-dihydroxy-thiophene-1,1-dioxide compounds and 3,4-dihydroxy-cyclopentadienone compounds BASF AKTIENGESELLSCHAFT (DE) 1978-10-24 US disclosed
US-4104196-A Nonabsorbable antioxidant method DYNAPOL (US) 1978-08-01 US disclosed
US-3994828-A Nonabsorbable antioxidant DYNAPOL CORPORATION (US) 1976-11-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11278634-B1 Stable parenteral composition of lacosamide LPXN, CACNA1A, AQP4 ALDH1A1 4216/4885MAPT 3330/4885MEN1 2180/4885
US-20230159569-A1 DUAL HDAC6/PROTEASOME INHIBITORS, AND METHODS OF USE THEREOF HDAC6, PSMG3, PSMB2 ALDH1A1 2269/4885MAPT 533/4885MEN1 4269/4885
US-20040210059-A1 Production of mixed acid anhydride and amide compound CA2, CA1, CA3 ALDH1A1 543/4885MAPT 4620/4885MEN1 2071/4885
US-20020032346-A1 Production of mixed acid anhydride and amide compound CA2, CA1, CA3 ALDH1A1 543/4885MAPT 4620/4885MEN1 2071/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.